Abbott Laboratories (ABT) Q3 FY2026 earnings: revenue $13.0 billion, up 14.5% on the year

Abbott Laboratories (ABT) announced its results for Q3 FY2026, the quarter ended 30 September 2026, on 21 October 2026. Revenue was $13.0 billion, up 14.5% on the same quarter a year earlier. Net income was $920 million, down 44.0% on the year, and diluted earnings per share $0.53. The figures are from the company's earnings press release; the 10-Q with the full statements is not filed yet, and this page fills in when it is.

Revenue$13.0 billionup 14.5%

Net income$920 milliondown 44.0%

Diluted EPS$0.53$0.94 a year earlier

QuarterQ3 FY2026ended 30 September 2026

What management said

Guidance figures: 1 lowered, 1 new, 1 kept.

Sales grew on both bases: Reported sales rose 14.5 percent to $13.0 billion; comparable growth of 7.0 percent includes Exact Sciences in both periods.
GAAP EPS fell; adjusted EPS rose: GAAP diluted EPS was $0.53 against $0.94 a year earlier; adjusted diluted EPS, excluding specified items, was $1.42 against $1.30.
Diagnostics grew with Exact Sciences: Diagnostics sales rose 46.7 percent reported and 6.4 percent comparable; the reported gap reflects the Exact Sciences acquisition.

Read the earnings call summary

The quarter, against the one before and a year earlier

Line	Q3 FY2026	Q2 FY2026	Q3 FY2025	Change on the year
Revenue	13,013	12,593	11,369	+14.5%
Net income	920	928	1,644	-44.0%
Diluted EPS	$0.53	$0.53	$0.94	-43.6%

$ million except per share.

Q3 FY2026 is from the company's press release of 21 October 2026; the other columns are from its 10-Q and 10-K filings. A release figure is shown when the release's own figure for an earlier quarter matches the filed one, so the line and its units are read right.

Quarterly results, the last 20 quarters filed

	Q3 FY2021	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	10,928	11,468	11,895	11,257	10,410	10,091	9,747	9,978	10,143	10,241	9,964	10,377	10,635	10,974	10,358	11,142	11,369	11,459	11,164	12,593
Cost of revenue	4,423	4,766	4,987	4,933	4,629	4,593	4,331	4,483	4,605	4,556	4,463	4,603	4,698	4,942	4,468	4,854	5,075	4,922	4,890	5,325
Gross profit	6,505	6,702	6,908	6,324	5,781	5,498	5,416	5,495	5,538	5,685	5,501	5,774	5,937	6,032	5,890	6,288	6,294	6,537	6,274	7,268
Gross margin	60%	58%	58%	56%	56%	54%	56%	55%	55%	56%	55%	56%	56%	55%	57%	56%	55%	57%	56%	58%
R&D	672	762	697	684	782	725	654	715	672	700	684	698	713	749	716	725	766	735	767	892
SG&A	2,767	3,048	2,787	2,757	2,731	2,973	2,762	2,740	2,723	2,724	2,959	2,936	2,895	2,907	3,061	3,091	3,051	3,129	3,740	4,025
Operating income	2,546	2,378	2,912	2,376	1,770	1,304	1,509	1,542	1,647	1,780	1,386	1,669	1,859	1,911	1,693	2,052	2,057	2,251	1,345	1,693
Operating margin	23%	21%	24%	21%	17%	13%	15%	15%	16%	17%	14%	16%	17%	17%	16%	18%	18%	20%	12%	13%
Interest expense	133	131	131	132	141	154	153	159	166	159	141	140	142	136	131	121	121	120	174	351
Pre-tax income	2,493	2,327	2,876	2,352	1,758	1,320	1,562	1,636	1,671	1,795	1,436	1,607	1,940	2,030	1,778	2,150	2,180	2,358	1,449	1,524
Tax rate	16%	15%	15%	14%	18%	22%	16%	16%	14%	11%	15%	19%	15%	-355%	25%	17%	25%	25%	26%	39%
Net income	2,100	1,989	2,447	2,018	1,435	1,033	1,318	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779	1,644	1,776	1,077	928
Net margin	19%	17%	21%	18%	14%	10%	14%	14%	14%	16%	12%	13%	15%	84%	13%	16%	14%	15%	10%	7%
Diluted EPS	$1.17	$1.11	$1.37	$1.14	$0.81	$0.59	$0.75	$0.78	$0.82	$0.91	$0.70	$0.74	$0.94	$5.27	$0.76	$1.01	$0.94	$1.01	$0.61	$0.53
Operating cash flow	2,701	3,067	2,065	2,410	2,780	2,326	1,143	1,203	1,877	3,038	1,025	1,960	2,705	2,868	1,417	2,047	2,787	3,315	1,315	2,488
Capital expenditure	461	614	321	379	467	610	380	507	560	755	398	533	556	720	484	502	496	689	399	497
Free cash flow	2,240	2,453	1,744	2,031	2,313	1,716	763	696	1,317	2,283	627	1,427	2,149	2,148	933	1,545	2,291	2,626	916	1,991
Buybacks	579	974	2,307	5.0	798	685	540	426	2.0	259	226	3.0	751	315	280	6.0	305	302	180	1,045
Dividends paid	801	798	832	828	826	823	890	890	888	888	957	961	960	958	1,026	1,029	1,031	1,030	1,098	1,102
Shares outstanding	1,768m	1,763m	1,751m	1,751m	1,744m	1,738m	1,739m	1,735m	1,736m	1,735m	1,740m	1,740m	1,734m	1,734m	1,740m	1,740m	1,739m	1,738m	1,742m	1,730m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Earnings press release for the quarter ended 30 September 2026, filed with the SEC on 21 October 2026 with a Form 8-K: the release.